Amendment: SEC Form SC 13G/A filed by Protagonist Therapeutics Inc.
$PTGX
Biotechnology: Pharmaceutical Preparations
Health Care
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/6/2024 | $47.00 | Neutral | Goldman |
| 12/6/2024 | $62.00 | Outperform | BMO Capital Markets |
| 11/5/2024 | $58.00 | Outperform | Wedbush |
| 9/24/2024 | $65.00 | Buy | TD Cowen |
| 9/9/2024 | $60.00 | Buy | Truist |
| 10/30/2023 | $32.00 | Overweight | CapitalOne |
| 5/25/2023 | $30.00 → $40.00 | Buy | Jefferies |
| 8/25/2022 | $21.00 | Mkt Outperform | JMP Securities |
4 - Protagonist Therapeutics, Inc (0001377121) (Issuer)
4 - Protagonist Therapeutics, Inc (0001377121) (Issuer)
4 - Protagonist Therapeutics, Inc (0001377121) (Issuer)
Goldman initiated coverage of Protagonist Therapeutics with a rating of Neutral and set a new price target of $47.00
BMO Capital Markets initiated coverage of Protagonist Therapeutics with a rating of Outperform and set a new price target of $62.00
Wedbush initiated coverage of Protagonist Therapeutics with a rating of Outperform and set a new price target of $58.00
− Study met the primary endpoint, with a significantly higher proportion of clinical responders on rusfertide compared to placebo − All four key secondary endpoints were met, including EU primary endpoint and patient-reported outcomes − Rusfertide was generally well tolerated; no new safety findings were observed in the study Protagonist Therapeutics, Inc. ("Protagonist") ((PTGX) and Takeda ((TAK) today announced positive topline results for the Phase 3 VERIFY study, in which phlebotomy-dependent patients with polycythemia vera (PV) were randomized to treatment with either rusfertide or placebo, as an add-on to standard of care treatment. The study met its primary endpoint and all fou
NEWARK, CALIFORNIA / ACCESSWIRE / January 6, 2025 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today reported that on January 2, 2025, it issued inducement awards to Newman Yeilding, M.D., upon his appointment to the role of Executive Vice President, Chief Scientific Officer, in accordance with the terms of his employment offer letter. Dr. Yeilding served in a consultant role as the Company's Chief Scientific Advisor from August 1, 2024 through January 1, 2025. The awards were granted under the Protagonist Therapeutics Amended and Restated Inducement Plan, which was adopted May 29, 2018, and amended February 18, 2020 and February 15, 2022.Dr. Yeilding received options to purchase 38,520 sh
NEWARK, CA / ACCESSWIRE / December 19, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will provide a company overview at the 43rd Annual J.P. Morgan Healthcare Conference taking place January 12-16, 2025 in San Francisco, CA. The Company will also participate in one-on-one meetings.43rd Annual J.P. Morgan Healthcare Conference - January 12-16, 2025Format: Company PresentationDay/Time: Tuesday, January 14 at 8:15AM PTWebcast: https://jpmorgan.metameetings.net/events/healthcare25/sessions/58274-protagonist-therapeutics-inc/webcast?gpu_only=true&kiosk=trueIf you are interested in meeting
Dr. Yeilding joins Protagonist from Janssen Pharmaceutical Companies of Johnson & Johnson, where he held leadership roles in the immunology therapeutic area, bringing extensive experience in R&D and commercialization of novel therapeutics in the I&I spaceNEWARK, CA / ACCESSWIRE / July 31, 2024 / Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced the appointment of Newman Yeilding, M.D. to the role of Chief Scientific Advisor, effective August 1, 2024. Dr. Yeilding is an accomplished physician-scientist with deep knowledge and expertise in inflammatory, rheumatology, autoimmune and immunologic diseases. As Chief Science Advisor, he will provide discovery,
NEW YORK, June 27, 2024 /PRNewswire/ -- Protagonist Therapeutics Inc. (NASD: PTGX) will replace Encore Wire Corp. (NASD: WIRE) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, July 3. S&P Europe 350 constituent Prysmian SpA (MTAA: PRY) is acquiring Encore Wire in a deal expected to be completed soon pending final conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector July 3, 2024 S&P SmallCap 600 Addition Protagonist Therapeutics PTGX Health Care S&P SmallCap 600 Deletion Encore Wire WIRE Industrials For more information a
SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced the appointment of industry veteran William Waddill to the Company's Board of Directors. The Company also announced that Patrick Machado has stepped down as a member of its Board of Directors. These changes became effective as of April 15, 2024. "I am pleased to welcome Will to our Board of Directors at this exciting time for Turnstone," said Sammy Farah, M.B.A.,
− Study met the primary endpoint, with a significantly higher proportion of clinical responders on rusfertide compared to placebo − All four key secondary endpoints were met, including EU primary endpoint and patient-reported outcomes − Rusfertide was generally well tolerated; no new safety findings were observed in the study Protagonist Therapeutics, Inc. ("Protagonist") ((PTGX) and Takeda ((TAK) today announced positive topline results for the Phase 3 VERIFY study, in which phlebotomy-dependent patients with polycythemia vera (PV) were randomized to treatment with either rusfertide or placebo, as an add-on to standard of care treatment. The study met its primary endpoint and all fou
Oral peptide with biologics-like high potency and spectrum of activity against three therapeutically relevant dimeric forms of IL-17 (AA, AF and FF)IND enabling studies underway, with Phase I initiation expected in Q425Webcast and conference call to be held today at 4:30 pm ET NEWARK, CA / ACCESSWIRE / November 21, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced the selection of PN-881, a potential best-in-class oral peptide interleukin-17 (IL-17) antagonist, as a development candidate for the treatment of immune-mediated skin diseases."We are extremely pleased to nominate development candidate PN-881, a promising potential best-in-class oral peptide IL
Webcast and conference call to be held be on Thursday, November 21st at 4:30 pm ET, dial in information belowNEWARK, CA / ACCESSWIRE / November 19, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that the company will host a conference call and webcast to announce its oral peptide IL-17 antagonist development candidate and to share in vitro and pre-clinical proof-of-concept study results.Conference Call and Webcast DetailsThe dial-in numbers for Protagonist's investor update on Thursday, November 21st at 4:30 pm ET are:US-based Investors: 1-877-407-0752International Investors: 1-201-389-0912Conference Call ID: 13750274The webcast link for the event can
SC 13G/A - Protagonist Therapeutics, Inc (0001377121) (Subject)
SC 13G/A - Protagonist Therapeutics, Inc (0001377121) (Subject)
SC 13G/A - Protagonist Therapeutics, Inc (0001377121) (Subject)
SCHEDULE 13G - Protagonist Therapeutics, Inc (0001377121) (Subject)
10-Q - Protagonist Therapeutics, Inc (0001377121) (Filer)
8-K - Protagonist Therapeutics, Inc (0001377121) (Filer)